Hamza is a gaming enthusiast and a Writing Specialist from Pakistan. A firm believer in Keyboard/Mouse supremacy, he will play Tekken with WASD if you let him. He has been writing about games since ...

One of Kril’s first tasks is to find a shell so he is not quite so….exposed. A drowned vending machine seems to have the answer, but in order to walk away with a shell—and alive—he must first defeat ...

Cash operating expenses for Q1 2025 were $2.9 million, down from $4.2 million in Q1 2024. Excluding non-cash stock-based compensation expense, these amounts were $2.7 million for Q1 2025 compared to ...

CEO Vincent Angotti highlighted significant progress in the NEPHRO CRRT study, emphasizing the FDA-approved reduction in study size from 166 to 70 patients while maintaining 90% statistical power for ...

Submission of a Prior Approval Supplement for a reduction in the number of patients in the NEPHRO CRRT study is expected within the coming week The FDA agreed to two additional protocol changes ...

SAN MATEO, Calif., Aug. 25, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative ...

Nephro Health initial public offering (IPO), which opened for subscription on Wednesday, December 11, received a muted response from investors across all three categories. The mainboard IPO was ...

The company will also showcase Foley-Safe, the world's first Foley catheter stabilizer that actively reduces the chance of infections and prevents accidental extractions. Cathetrix will launch ...

Vincent J. Angotti, CEO, highlighted “the progress made this past quarter, specifically in the acceleration of the NEPHRO study enrollment” and detailed the impact of restructuring efforts, stating ...

The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing ...